Orexigen buys U.S. rights to obesity drug from Takeda

Tue Mar 15, 2016 7:27am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

March 15 (Reuters) - Orexigen Therapeutics Inc said it would pay $60 million to acquire the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co .

Orexigen said it had also entered into a deal with Canada's Valeant Pharmaceuticals International Inc to sell the treatment in central and eastern Europe. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)